⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 16, 2010The Journal of Clinical Endocrinology & MetabolismOpen Access

Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus

View Full Paper

Ask AI

Bookmark

Share

Abstract

Pioglitazone improves insulin resistance in T2DM in association with mobilization of fat and toxic lipid metabolites out of muscle.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bajaj et al. (2010) studied this question.

synapsesocial.com/papers/69d9a50fed2e131d3c68425e https://doi.org/10.1210/jc.2009-0911

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

1Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated Phosphatidylinositol 3-Kinase Activity in MuscleOriginal Research · 2002 · 1,567 citations
2A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and DyslipidemiaOriginal Research · 2005 · 796 citations
3Glucose clamp technique: a method for quantifying insulin secretion and resistance.Original Research · 1979 · 7,495 citations